about
Brn-2 expression controls melanoma proliferation and is directly regulated by beta-cateninRestoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPPBrachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter.The Brn-2 transcription factor links activated BRAF to melanoma proliferationPositive and negative elements regulate a melanocyte-specific promoterMitf regulation of Dia1 controls melanoma proliferation and invasivenessViral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain.The ISWI and CHD1 chromatin remodelling activities influence ADH2 expression and chromatin organization.Regulated displacement of TBP from the PHO8 promoter in vivo requires Cbf1 and the Isw1 chromatin remodeling complex.The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytesThe Usf-1 transcription factor is a novel target for the stress-responsive p38 kinase and mediates UV-induced Tyrosinase expression.The RING domain of RAG1 ubiquitylates histone H3: a novel activity in chromatin-mediated regulation of V(D)J joiningUV-induced expression of key component of the tanning process, the POMC and MC1R genes, is dependent on the p-38-activated upstream stimulating factor-1 (USF-1)Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers.Targeting the microphthalmia basic helix-loop-helix-leucine zipper transcription factor to a subset of E-box elements in vitro and in vivoNFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.Cancer stem cells versus phenotype-switching in melanoma.Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanomaTbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor.Directed phenotype switching as an effective antimelanoma strategy.Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.Chromatin barcodes as biomarkers for melanoma.Cell cycle regulation of the T-box transcription factor tbx2.The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3Tbx3 represses E-cadherin expression and enhances melanoma invasiveness.Beta-catenin in the melanocyte lineage.Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.S1 sensitive sites in adenovirus DNA.The transcription network regulating melanocyte development and melanoma.Mitf is a master regulator of the v-ATPase, forming a control module for cellular homeostasis with v-ATPase and TORC1.Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development.MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.TBX2 expression is regulated by PAX3 in the melanocyte lineageThe melanocyte inducing factor MITF is stably expressed in cell lines from human clear cell sarcomaMelanocytes: the new Black.Afamelanotide for Erythropoietic Protoporphyria.Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development.Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.MC1R is a potent regulator of PTEN after UV exposure in melanocytes
P50
Q24317170-C5ED0AC4-7A0E-49DD-9E11-BD941236A565Q24339404-53490AF3-6E71-4689-BC46-F62265991F5EQ24522646-81D6AC53-15BC-465B-9003-F125D2B8BDB2Q24599712-C3030218-33A2-4861-B0D1-C7E9358325E0Q24629845-A3D40388-30E3-4976-976F-C24BFC2C6C2AQ24672631-3228931C-E6C2-4AE1-A02A-B9D097047A5EQ24815194-D53A7112-2D35-4617-A41F-5FF07AE3902CQ27931612-E5641C48-56BF-4AC3-91EF-B7FBBB3A8681Q27933737-E599C07A-DBBB-40DD-9FF6-60C3606A5F79Q28142253-335497EC-EC53-4AE6-BCB3-F5F6237C7439Q28348605-D318BDC6-1AE5-4CCF-86E3-056A1C761266Q28512772-72D49ECC-3BE0-4379-9D44-5E3B02226A09Q28592680-3A41CC45-A962-4EE6-9F01-3E5BC59F0548Q30491014-65A124DA-D041-430E-BC0C-29BA4B6AB996Q30829456-7CB3BEF2-F049-4572-8522-E95BF93D5714Q33781625-FC031883-8DCC-4089-A5B8-447607CBBD9BQ33809465-5BD85C96-A71D-4578-AB40-4D86DAFF588CQ34132378-92ADE436-61A9-43C2-B604-B0A595DE2E3EQ34221697-36F721D6-D79F-4B17-BD43-F581D0DC6941Q34302649-AE20F710-A0E6-41B1-B582-B366FFF9D994Q34352683-E68A1D57-FAB9-4B79-AFA1-BE3D3AF1A191Q34405159-71488683-3C6B-45B3-8C62-0581C07916AEQ34419273-43CE6E07-3602-4D92-86C5-3DE8387C62A9Q34531382-58B099DA-3399-4FBF-8334-0D246B9377EEQ34738135-2D225EF6-B112-4793-9FC0-871600A3A03CQ34842421-3AA19D1F-1C99-4237-A89A-4E1AAAEA1FC5Q35129949-7DDD283B-F82A-448E-968F-A6116AF744E9Q35596369-B5B726D4-6908-44DF-BE9D-5AA115C50162Q35668802-C25950E7-AB6E-4024-8730-FC39A5905890Q35834767-D95DA3E1-F447-4BE0-8916-760C0DC10ABAQ35968782-6772F581-C693-43EB-BA8A-2E8B8E9CA3B7Q36103651-FFBD8566-E4CA-4D1F-8E50-AB3D61D64A08Q36320144-2BD47B6F-613C-4FAD-97FF-C8A74698F119Q36481040-BACD3AA0-4C8D-4963-A058-3070727922DAQ36648458-349FF090-38D1-4D14-B4B3-881A3F891819Q36649269-BAA703D7-0596-42C9-B822-BC8FF93E706AQ36657737-18BBCB57-ECCE-4680-B3D6-713FBCD6CF64Q37031888-A996EB83-2958-48CA-B2B8-71D42AE3354FQ37210779-4AFFBDB6-C906-4960-8EA1-1A4F195E87E4Q37220171-EDFE5E7F-2156-49AF-8394-B6045371E763
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Colin R Goding
@nl
Colin R Goding
@sl
Colin R. Goding
@en
Colin R. Goding
@es
type
label
Colin R Goding
@nl
Colin R Goding
@sl
Colin R. Goding
@en
Colin R. Goding
@es
prefLabel
Colin R Goding
@nl
Colin R Goding
@sl
Colin R. Goding
@en
Colin R. Goding
@es
P106
P1153
35552696600
P21
P31
P496
0000-0002-1614-3909